Escitalopram


S-enantiomer SSRI

The (S)-enantiomer of citalopram; the active component of the racemate marketed as a separate antidepressant with improved tolerability.

Abstract

Escitalopram (S-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 128196-01-0; molecular formula C20H21FN2O; molecular weight 324.39) is the (S)-enantiomer of citalopram, marketed as Lexapro by H. Lundbeck and Forest Pharmaceuticals after FDA approval in 2002. SERT affinity is approximately 1 nM; selectivity for SERT over NET and DAT is the highest of any clinical SSRI. The active enantiomer is responsible for essentially all SERT inhibitory activity in racemic citalopram; the (R)-enantiomer attenuates (S) binding through an allosteric SERT interaction, so removing it produces a small but measurable increase in serotonergic efficacy per milligram. Plasma half-life is approximately 27 to 32 hours, slightly shorter than racemic citalopram. Hepatic metabolism via CYP2C19 with secondary CYP3A4 and CYP2D6 contribution. The compound exhibits the QTc prolongation profile of racemic citalopram but with a cleaner adverse event signature owing to the absence of the (R)-enantiomer. Approved for major depressive disorder and generalized anxiety disorder. Used as a high-purity SERT-selective reference compound in mechanism studies.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph